GHK-Cu as an Analytical Problem: Copper Coordination, Speciation and What Identity and Purity Testing Should Show

RESEARCH · GHK-CU · COORDINATION & ANALYSIS

GHK-Cu as an Analytical Problem: Copper Coordination, Speciation and What Identity and Purity Testing Should Show

PurixLab’s GHK-Cu 50mg is a research vial of the copper(II) complex of glycyl-L-histidyl-L-lysine. Our earlier articles cover a copper-peptide research overview and skin permeation and delivery, and our guide to reading a peptide COA explains HPLC and mass-spectrometry results in general. This article asks why a copper complex is harder to characterise than an ordinary peptide: which species the coordination-chemistry literature says are present, and which measurements would actually describe a GHK-Cu sample. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.

A peptide that arrives with its metal

When GHK was isolated from plasma it co-isolated through a number of steps with approximately equimolar copper and about 1/5 molar iron, and the tripeptide readily formed complexes with copper(II) and enhanced the metal’s uptake into cultured hepatoma cells [1]. The same work pointed to a similarity with the copper-transport sites of albumin and alpha-fetoprotein, where copper is bound to a histidyl residue adjacent to a basic residue [1]. A later review places GHK among N-terminal Xxx-Zzz-His motifs that form well-established high-affinity Cu(II) complexes, alongside the Asp-Ala-His sequence of serum albumin [2].

What the copper is bound to

Optical, EPR and electron spin-echo spectroscopy showed a mononuclear 1:1 Cu(II) complex at neutral pH with equatorial nitrogen coordination including the histidyl imidazole, three pH-dependent transitions with apparent pKs of 3.6, 9.2 and 11.4, and a polymeric solid-state structure with oxygen-bridged copper pairs that does not exist in solution [3]. EPR spectra between pH 6.0 and 9.6 showed seven-line nitrogen superhyperfine splitting from three coordinated nitrogen atoms, with parallel parameters of 19.5 mT and g = 2.21; the same study cautioned that NMR line-broadening by paramagnetic Cu(II) reflects minor species in rapid exchange and may not be useful for structural information on the major species [4].

X-ray and multi-spectroscopic work confirmed a monomeric solution complex with three nitrogen ligands (amine, amidyl and imidazole) and a labile fourth equatorial position. Copper exchange between GHK molecules was fast, attributed to a [Cu(GHK)2] complex, and Cu(II)GHK could be reduced to Cu(I) around −0.62 V versus AgCl/Ag with subsequent release of the copper ion [5].

Speciation: one label, several species

Potentiometric titrations between pH 3.5 and 10.6 found multiple species in the binary copper–GHK system and extensive ternary complexes when histidine was present; at equimolar albumin and peptide, about 42% of the Cu(II) was bound to the peptide [6]. A comparison with synthetic analogues using potentiometry, calorimetry, UV-VIS, circular dichroism and EPR found complexes of different stoichiometries, including binuclear species, and suggested that the lysine side-chain amino group joins the complex only at alkaline pH [7]. Human serum albumin forms ternary Cu(GHK) complexes through histidine side chains, with a conditional binding constant of 2900 M-1 at His3 at pH 7.4 [8]. Glutathione, the strongest natural reductant in plasma, reduces Cu(II)GHK through a transient GSH–Cu(II)GHK intermediate [9], and ESI-MS has been used to follow GHK, GHK-Cu and (GHK)2-Cu species across pH media [10].

In practice, a powder labelled GHK-Cu is a solid whose structure differs from what forms after it dissolves, and whose speciation then depends on pH, copper-to-peptide ratio and any other ligands present [3,5,6].

What identity and purity testing can show

Reversed-phase HPLC is the workhorse. A preformulation study quantified GHK with a validated stability-indicating RP-HPLC method; HPLC with mass spectrometry identified three key degradation products, one of which was histidine, and GHK-Cu was highly hydrophilic, with log D values between −2.38 and −2.49 at pH 4.5–7.4 [11]. An ion-pair HPLC method with post-column o-phthalaldehyde derivatisation measured GHK and its metabolite His-Lys in rat plasma, with detection limits of 50 and 15 ng/ml, and showed that GHK was rapidly degraded to HK [12]. These methods measure the peptide; on their own they do not say how much copper is bound or in what form.

Copper-specific methods exist. Capillary electrophoresis coupled to ICP tandem mass spectrometry (CE-ICP-MS/MS), which can analyse species in their intact form under mild conditions, has tracked copper and phosphorus signals to assess GHK-Cu encapsulation in liposomes [13] and liposome stability in cosmetic emulsions and serums [14]. Fluorescent dansyl peptide probes quantify Cu(II) affinities from micromolar to femtomolar on a unified scale and reproduced previously reported affinities for GHK and DAHK [15]. A 2026 evidence-mapping review notes that delivery studies often report total peptide or copper content, whereas molar occupancy, labile copper and release of intact GHK-Cu versus apo-GHK or free copper are usually not resolved [16].

Ordinary peptide impurities still apply

GHK-Cu is still a synthetic peptide. A review of peptide medicines lists deletion and insertion sequences from solid-phase synthesis, racemisation, protection-group adducts, side-chain oxidation and counter-ions such as trifluoroacetate [17]. Among three techniques compared for acetate, trifluoroacetate and chloride counter-ions, ion chromatography gave the best results [18]. In a reference-material study of angiotensin II, the trifluoroacetic acid counter-ion made up nearly 25% by mass and the final purity value was 691 ± 9 mg/g [19], a reminder that HPLC area percent is not peptide content by weight.

What a GHK-Cu certificate would ideally report

  • Identity. The observed mass of GHK and, where the method preserves it, of the copper complex [10].
  • Purity. An RP-HPLC chromatogram that resolves degradation products such as histidine [11].
  • Copper content. Total copper relative to peptide, ideally with molar occupancy and labile or free copper [16,13].
  • Counter-ions. Counter-ion content by ion chromatography or similar, so that net peptide content can be estimated [18,19].
  • Conditions. The solvent and pH of any solution measurement, because species distribution depends on them [6,7].

This list is our inference from the analytical literature, not an agreed standard: as of 2026-10-18 we found no PubMed-indexed consensus method specific to GHK-Cu research material.

GHK-Cu 50mg at PurixLab

GHK-Cu 50mg: a labelled lyophilized research vial with 50mg per vial, C$49 per vial (CAD, before tax), supplied for laboratory research only. It is not a cosmetic; our separate Copper Facial Mask is the finished cosmetic product. Batch documentation is available on request. Product page: purixlab.com/product/ghk-cu-50mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View GHK-Cu 50mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Pickart L, Freedman JH, Loker WJ, et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-7. PubMed 7453802 · doi:10.1038/288715a0
  2. Gonzalez P, Bossak K, Stefaniak E, et al. N-Terminal Cu-Binding Motifs (Xxx-Zzz-His, Xxx-His) and Their Derivatives: Chemistry, Biology and Medicinal Applications. Chemistry. 2018;24(32):8029-8041. PubMed 29336493 · PMC6152890 · doi:10.1002/chem.201705398
  3. Freedman JH, Pickart L, Weinstein B, et al. Structure of the Glycyl-L-histidyl-L-lysine–copper(II) complex in solution. Biochemistry. 1982;21(19):4540-4. PubMed 6291585 · doi:10.1021/bi00262a004
  4. Laussac JP, Haran R, Sarkar B. N.m.r. and e.p.r. investigation of the interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1983;209(2):533-9. PubMed 6303307 · PMC1154122 · doi:10.1042/bj2090533
  5. Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-60. PubMed 21780203 · doi:10.1002/chem.201100751
  6. Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981;199(3):649-56. PubMed 7340824 · PMC1163421 · doi:10.1042/bj1990649
  7. Conato C, Gavioli R, Guerrini R, et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochim Biophys Acta. 2001;1526(2):199-210. PubMed 11325542 · doi:10.1016/s0304-4165(01)00127-1
  8. Bossak-Ahmad K, Bal W, Frączyk T, et al. Ternary Cu2+ Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorg Chem. 2021;60(22):16927-16931. PubMed 34730942 · doi:10.1021/acs.inorgchem.1c03084
  9. Ufnalska I, Drew SC, Zhukov I, et al. Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione: A Handy Chelate for Biological Cu(II) Reduction. Inorg Chem. 2021;60(23):18048-18057. PubMed 34781677 · PMC8653159 · doi:10.1021/acs.inorgchem.1c02669
  10. Mazurowska L, Mojski M. ESI-MS study of the mechanism of glycyl-l-histidyl-l-lysine-Cu(II) complex transport through model membrane of stratum corneum. Talanta. 2007;72(2):650-4. PubMed 19071668 · doi:10.1016/j.talanta.2006.11.034
  11. Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016;21(2):152-60. PubMed 25384620 · doi:10.3109/10837450.2014.979944
  12. Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl. 1997;692(1):37-42. PubMed 9187381 · doi:10.1016/s0378-4347(96)00460-4
  13. Zajda J, Wadych E, Ogórek K, et al. Novel Applications of CE-ICP-MS/MS: Monitoring of Antiaging GHK-Cu Cosmetic Component Encapsulation in Liposomes. Electrophoresis. 2024;45(21-22):1946-1954. PubMed 39451062 · doi:10.1002/elps.202400047
  14. Ogórek K, Mierzwa M, Drozd M, et al. Characterization of copper tripeptide-loaded lipid carriers and their stability in complex cosmetic matrices. J Chromatogr A. 2026;1789:467540. PubMed 42887096 · doi:10.1016/j.chroma.2026.467540
  15. Young TR, Wijekoon CJ, Spyrou B, et al. A set of robust fluorescent peptide probes for quantification of Cu(ii) binding affinities in the micromolar to femtomolar range. Metallomics. 2015;7(3):567-78. PubMed 25715324 · doi:10.1039/c4mt00301b
  16. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026;18(9):1077. PubMed 42797253 · PMC13610439 · doi:10.3390/pharmaceutics18091077
  17. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed 25044089 · doi:10.1016/j.jpba.2014.06.012
  18. Mrozik W, Markowska A, Guzik L, et al. Determination of counter-ions in synthetic peptides by ion chromatography, capillary isotachophoresis and capillary electrophoresis. J Pept Sci. 2012;18(3):192-8. PubMed 22252914 · doi:10.1002/psc.1436
  19. Melanson JE, Thibeault MP, Stocks BB, et al. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410(26):6719-6731. PubMed 30143839 · doi:10.1007/s00216-018-1272-7

Leave a Comment

Your email address will not be published. Required fields are marked *